As development continues for a “4-in-1” fixed-dose combination (abacavir/lamivudine/ lopinavir/ritonavir) for young children, interim results of the LIVING study for an optimized “2-in-1” lopinavir/ritonavir paediatric formulation were released. The study – which enrolled over 1,000 children in sub-Saharan Africa – showed that 83% of children were virologically suppressed at 48 weeks, compared to 55% at the beginning of the study.
by Rabie H, Denti P, Lee J, Masango M, Coovadia A, Pillay S, Liberty A, Simon F, McIlleron H, Cotton MF, Lallemant M.
The Lancet HIV, January 2019
by Pasipanodya B, Kuwengwa R, Prust ML, Stewart B, Chakanyuka C, Murimwa T, Brophy J, Salami O, Mushavi A, Apollo T.
Journal of the International AIDS Society, December 2018
Standard Digital News Kenya [27 October 2018]
“Ray of hope for children with HIV and Aids”
In early October, 18 journalists from 11 African countries converged in Kampala, Uganda for DNDi’s first-ever training on health and science journalism. The three-day training was conducted during a week of workshops and meetings related to the work of DNDi and its many partners, culminating in the 11th DNDi Partners’ Meeting on 4 October 2018.
The Citizen [11 October 2018]
“Children’s HIV drug formula developed”
Ghana Web [11 October 2018]
“Pediatric HIV victims get attention”
Daily Monitor [10 October 2018]
“HIV-positive children to take soluble ARVs”
New Business Ethiopia [3 October 2018]
“New clinical trials for neglected diseases in eastern Africa in progress”
24-27 October 2018
Johannesburg, South Africa
- Carol Ruffel, Head of DNDi South Africa Office – session on infant HIV testing
Daily Nation [26 June 2018]
“Child-friendly antiretrovirals in the pipeline”
24 May 2018
DNDi and MMV, supported by Unitaid, delivered a statement on the progress made by WHO in developing a Global Framework on Nurturing Care for Early Childhood Development. The statement calls for R&D and access to child-friendly medicines, and open data sharing of research findings.
3-4 October 2018
- François Bompart, Director of Paediatric HIV/HCV Programmes, Isabelle Andrieux-Meyer, Head of Clinical Development Paediatric HIV/HCV Programmes, Jean-René Kiechel,Expert in R&D – panel discussion on DNDi‘s journey so far working on Paediatric HIV
- Olawale Salami, Paediatric HIV Clinical Project Manager – panel discussion on access to child-adapted ARV formulations
23-27 July 2018
Amsterdam, the Netherlands
Side event on ending paediatric HIV, presentation on the LIVING study on paediatric HIV, two panel discussions, and poster discussion on TB/HIV co-treatment, and poster on caregiver adherence to oral lopinavir/ritonavir pellets to treat children.
Also: pre-conference workshop session on viral suppression in children taking oral LPV/r
The East African [11 April 2018]
“Uganda leads study for new HIV drug for children”
29 May-1 June 2018
DNDi – poster presentation on TB/HIV paediatric co-treatment
24-25 May 2018
Olawale Salami, Paediatric HIV Clinical Project Manager DNDi Africa – poster about the LIVING study on treatment for paediatric HIV
7th Edition: Precision Global Health in the Digital Age
10-12 April 2018
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth
27 January 2018
Medicines for Malaria Venture and DNDi delivered a joint statement at WHO’s Executive Board 142, urging WHO to recognize the urgent need for research and development, access, and uptake of child-friendly medicines.